Are there mortality risks for patients with epilepsy who use cannabis treatments as monotherapy?

Two cases of sudden death are reported in patients whose self-determined seizure management primarily relied on artisanal cannabis therapies. Risks of morbidity, mortality and SUDEP in SDTC users need to be further studied. Providers should be aware of the absence of morbidity and mortality data for SDTC in patients with epilepsy may only be due to a failure of reporting.